SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer

Bookmark and Share
Published: 6 Nov 2020
Views: 252
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

Prof Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning durvalumab compared to maintenance chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

Prof Barlesi initially outlines the trial design and patient body, before giving results concerning each patient cohort.